Compare Lululemon Athletica Inc (LULU) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Zoetis Inc — how do they compare? Lululemon Athletica Inc trades at $94.5 (market cap $10.27B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.9× Lululemon Athletica Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 105 Days and Zoetis Inc for 70 Days on average.
| LULU | ZTS | |
|---|---|---|
Market Cap | $10.27B | $30.20B |
Volume | 4,392,324 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $147.53 |
52-Week Low | $91.88 | $69.09 |
Typical Hold Time | 105 Days | 70 Days |
Enterprise Value | $11.02B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon stock trades at $94.5, down 54% year-to-date and near its 52-week low, reflecting a bearish technical trend. Despite strong profitability with a 12.78% net income margin and a low P/E of 7.63, the stock faces headwinds from recent revenue declines and multiple securities fraud investigations. Earnings have beaten estimates in recent quarters, but negative sentiment and governance concerns weigh on investor confidence.
The outlook remains cautious; the stock's deep discount to historical valuations presents a potential opportunity, but risks from legal probes, competitive pressures, and weak growth visibility suggest limited near-term upside. Analyst consensus is mixed with a $97.67 price target, indicating modest potential from current levels amid high uncertainty.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
